VSTM Stock Recent News

In the vast landscape of today's markets, artificial intelligence (AI) is reshaping investment strategies. Therefore, AI stock picks are as relevant as ever.

Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each using avutometinib with two different types of KRAS G12C inhibitors for the treatment of KRAS G12C NSCLC, expected mid-2024. The global non-small cell lung cancer market is expected to reach $38.8 billion by 2030; About 13% of NSCLC patients have the KRAS G12C mutation.

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.

Verastem (VSTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market or to convert Accelerated Approval to Full Approval. Company entered into a collaboration agreement with GenFleet Therapeutics to expand its pipeline and strengthen its position in the RAS driven cancer pathway space.

Verastem is a biotechnology company focused on developing novel agents for solid tumors, with its main candidate being avutometinib. Avutometinib is being studied in various cancers, driven by RAS pathway activation, with promising early results in relapsed/refractory low-grade serous ovarian carcinoma. Verastem has sufficient cash to reach a new milestone in 2024 or early 2025, but more data is needed to determine if avutometinib is a viable solution in solid tumor oncology.

BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference; podium presentation on Tuesday, September 12, 2023 at 2:00 p.m. ET 2023 Cantor Global Healthcare Conference; fireside chat on Tuesday, September 26, 2023 at 9:55 a.m. ET A live webcast of the.

Verastem Oncology presented promising data from their RAMP 201 program of Avutometinib monotherapy or in combination with Defactinib for the treatment of LGSOC. The market was impressed with the data and VSTM is trading up over 100% from a month ago. It appears as if the market might have regained some conviction in Avutometinib and its ability to work in KRAS mutant and other cancers.

Trading penny stocks can be an exhilarating venture, offering the potential for significant returns. These low-cost shares, often priced under $5, represent a unique opportunity to participate in the growth of emerging companies, particularly in the dynamic tech sector.

The tech sector, a perpetually booming industry, presents an ocean of opportunities for investors, particularly those interested in trading penny stocks. These are low-priced stocks, typically trading for less than five dollars a share, representing smaller companies, including startups and those navigating through periods of financial recovery.